Product Information
ATORVASTATIN 40 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.0374 per EA under NDC 00904629261. Its NADAC has been published 610 times since Jan 28, 2015.
FDA first approved this application on May 29, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the ATORVASTATIN CALCIUM market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904629261
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATEApproval Type
Generic (ANDA)
FDA Application
ANDA090548FDA Approved
5/29/2012
TE Code
AB
On Market Since
10/31/2014
Pharmacological Classes
Price Statistics
The NADAC for ATORVASTATIN 40 MG TABLET has been published 610 times since Jan 28, 2015, and over the history we have for it it has declined 76.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0374 per EA |
|---|---|
| All-time high | $0.1832 (Mar 11, 2015) |
| All-time low | $0.0370 (Aug 19, 2026) |
| 52-week high | $0.0426 |
| 52-week low | $0.0370 |
| Median price | $0.0769 |
| Average price | $0.0860 |
| Largest weekly change | +27.7% (Aug 21, 2024) |
| Weeks tracked | 610 |
| Tracking since | Jan 28, 2015 |
Generic Alternatives
The matcher finds 10 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ATORVASTATIN CALCIUM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
HMG-CoA Reductase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATORVASTATIN 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ATORVASTATIN 40 MG TABLET, manufactured by Major Pharmaceuticals, is $0.0374 per EA (NDC 00904629261), effective Sep 30, 2026.
How has the price of ATORVASTATIN 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for ATORVASTATIN 40 MG TABLET has declined 76.6%. It has been tracked across 610 weekly CMS publications since Jan 28, 2015.
What are the highest and lowest recorded NADAC prices for ATORVASTATIN 40 MG TABLET?
Since Jan 28, 2015, the NADAC for ATORVASTATIN 40 MG TABLET has ranged from a low of $0.0370 (Aug 19, 2026) to a high of $0.1832 (Mar 11, 2015), with a median of $0.0769 per EA.
Are there cheaper alternatives to ATORVASTATIN 40 MG TABLET?
Yes. 10 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ATORVASTATIN 40 MG TABLET, is $0.0374 per EA — about 0% below ATORVASTATIN 40 MG TABLET.
Who manufactures ATORVASTATIN 40 MG TABLET?
ATORVASTATIN 40 MG TABLET (NDC 00904629261) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.